NCT01672138

Brief Summary

This study aims to examine the long-term success rate of catheter ablation in non-paroxysmal atrial fibrillation patients using different ablation strategies such as : (i) pulmonary vein antrum isolation (PVAI) + isolation of left atrial posterior wall, (ii) PVAI plus scar homogenization, (iii) PVAI plus isolation of posterior wall plus ablation of non-PV triggers \[ PVAI: Pulmonary Vein Antrum Isolation Non-PV triggers: Triggers arising from sites other than pulmonary veins\]

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
186

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 21, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 24, 2012

Completed
5 months until next milestone

Study Start

First participant enrolled

February 1, 2013

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

November 16, 2018

Status Verified

November 1, 2018

Enrollment Period

6.8 years

First QC Date

August 21, 2012

Last Update Submit

November 14, 2018

Conditions

Keywords

PVAINPAFNon-PV triggers

Outcome Measures

Primary Outcomes (1)

  • Recurrence of atrial arrhythmia

    Any episode of AF/AT (atrial tachycardia) longer than 30 seconds will be considered as recurrence). Episodes that occur during the first 3 months of the procedure (blanking period) will not be considered as recurrence.

    3 years

Secondary Outcomes (1)

  • Improvement in quality of life

    3 years

Study Arms (3)

Control

ACTIVE COMPARATOR

Pulmonary Vein Antrum Isolation (PVAI) + isolation of left atrial posterior wall

Procedure: Pulmonary Vein Antrum Isolation

Study I

ACTIVE COMPARATOR

PVAI+ scar homogenization

Procedure: Pulmonary Vein Antrum IsolationProcedure: scar homogenization

Study II

ACTIVE COMPARATOR

PVAI + isolation of left atrial posterior wall + non-PV triggers ablation

Procedure: Pulmonary Vein Antrum IsolationProcedure: scar homogenizationProcedure: Non-PV triggers ablation

Interventions

Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall

Also known as: PVAI
ControlStudy IStudy II

PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.

Study IStudy II

PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites

Study II

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years
  • Patients undergoing first catheter ablation for drug-refractory Persistent (PerAF) or long-standing persistent AF (LSPAF)
  • Ability to understand and provide signed informed consent

You may not qualify if:

  • Previous catheter ablation or MAZE procedure in left atrium
  • Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis, pulmonary embolism etc

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

St. david's medical Center

Austin, Texas, 78705, United States

RECRUITING

Texas Cardiac arrhythmia Institute, St. David's Hospital

Austin, Texas, 78705, United States

RECRUITING

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Andrea Natale, MD

    TCAI

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Andrea Natale, MD

CONTACT

Mitra Mohanty, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Executive medical director, TCAI

Study Record Dates

First Submitted

August 21, 2012

First Posted

August 24, 2012

Study Start

February 1, 2013

Primary Completion

December 1, 2019

Study Completion

December 1, 2020

Last Updated

November 16, 2018

Record last verified: 2018-11

Locations